Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971939 · ClinicalTrials.gov registry record · Phase 4
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
A Phase 4 study, sponsored by Neurotech Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 285
- Enrollment target
NCT06971939: Recruiting Phase 4 study, sponsored by Neurotech Pharmaceuticals.
NCT06971939 is a Phase 4 study that is actively recruiting participants, run by Neurotech Pharmaceuticals. The registered enrollment target is 285 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06971939, a Phase 4 study, is actively recruiting participants, sponsored by Neurotech Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received the intraocular implant in a Phase 1, Phase 2, or Phase 3 clinical study. In addition, this study will evaluate the safety and efficacy of NT501 in participants who previously underwent the sham procedure in a Phase 3 MacTel clinical study and elect to have NT-501 implanted intraocularly in this Phase 4 study.
Primary Outcome
Incidence of ocular and nonocular adverse events (AEs) and serious adverse events (SAEs)
Interventions
- COMBINATION_PRODUCT NT-501/revakinagene taroretcel-lwey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2032-01-15 |
| Phase | Phase 4 |
What NCT06971939 shows while recruiting
NCT06971939 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 1 intervention - of which NT-501/revakinagene taroretcel-lwey is the first listed.
NCT06971939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06971939 about?
NCT06971939 is a clinical study titled "Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants". The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants with macular telangiectasia type 2 (MacTel) who previously received th...
What is the current status of trial NCT06971939?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 285 participants. The study started on 2025-11-21. Estimated completion is 2032-01-15.
What interventions are being tested in trial NCT06971939?
The interventions under investigation include: NT-501/revakinagene taroretcel-lwey (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06971939?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06971939's enrollment target sits among peer trials
285 302nd of 2000 higher than 1,699 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI